Treatment of shigellosis : V. Comparison of Azithromycin and ciprofloxacin a double-blind, Randomized, controlled trial.
Treatment of shigellosis is currently limited by the high prevalence of multidrug-resistant strains of Shigella.
To determine the efficacy of azithromycin in the treatment of shigellosis.
Randomized, double-blind clinical trial.
Diarrhea treatment center in Dhaka, Bangladesh.
70 men with shigellosis that had lasted 72 hours or less.
Patients stayed in the hospital for 6 days.
Thirty-four patients were randomly assigned to receive 500 mg of azithromycin on study day 1, followed by 250 mg once daily for 4 days ; 36 patients were assigned to receive 500 mg of ciprofloxacin every 12 hours for 5 days.
Clinical treatment failure was considered to have occurred if frank dysentery persisted for 72 hours after therapy began or if on study day 5 a patient had more than six stools, had any bloody-mucoid stools, had more than one watery stool, or had an oral body temperature exceeding 37.8 °C. Bacteriologic treatment failure was considered to have occurred if Shigella strains could be isolated from a stool sample after study day 2. Therapy was considered either clinically or bacteriologically successful in patients who completed therapy and did not meet criteria for failure.
Therapy was clinically successful in 28 (82%) patients who received azithromycin and 32 (89%) patients who received ciprofloxacin (difference, - 7% [95% Cl, - 23% to 10% ]). (...)
Mots-clés Pascal : Shigellose, Bactériose, Infection, Chimiothérapie, Etude double insu, Azithromycine, Etude comparative, Pharmacocinétique, Ciprofloxacine, Evaluation, Homme, Bengla Desh, Asie, Macrolide, Fluoroquinolone dérivé, Quinolone dérivé, Appareil digestif pathologie, Intestin pathologie, Organisation santé, Antibiotique, Antibactérien
Mots-clés Pascal anglais : Shigellosis, Bacteriosis, Infection, Chemotherapy, Double blind study, Azithromycin, Comparative study, Pharmacokinetics, Ciprofloxacin, Evaluation, Human, Bangladesh, Asia, Macrolide, Fluoroquinolone derivatives, Quinolone derivatives, Digestive diseases, Intestinal disease, Public health organization, Antibiotic, Antibacterial agent
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0368260
Code Inist : 002B02S02. Création : 12/09/1997.